Comparison tool

TB-500 vs BPC-157 side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

TB-500BPC-157

Share this peptide comparison

Property	TB-500	BPC-157
Category	Healing	Healing
Also known as	Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment	Body Protection Compound-157, Pentadecapeptide BPC 157
FDA approved	No	No
Clinical status	Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026) Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Phase 2 recruiting (NCT07437547); investigational. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Muscle recovery, wound healing, injury rehabilitation	Injury recovery, gut healing, joint and tendon repair
How it works	TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.	The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.
Typical dosing	2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly	250-500 mcg twice daily · 1-2x daily
Research dosing	2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection	250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic
Typical duration	4-6 weeks loading, then maintenance	4-12 weeks in most research protocols
Administration	Subcutaneous or intramuscular injection	Subcutaneous injection near injury site, or systemic
Timing	Morning or evening With or without food	Morning and evening (or near injury site timing) With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.) Injection site reactions Headache +7 more Fatigue Nausea May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.) Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.) Contraindicated with active cancer or cancer history (Source-supported contraindication note.) Limited long-term safety data WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)	Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.) Nausea (Listed by the source without frequency or causality information.) Dizziness (Listed by the source without frequency or causality information.) +6 more Injection site reactions (Listed by the source without frequency or causality information.) Fatigue (Listed by the source without frequency or causality information.) Headache (Listed by the source without frequency or causality information.) May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.) Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.) Limited long-term human safety data (The source itself notes limited long-term human safety information.)
Research summary	The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.	According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.
References	Source Source +2 more Source Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

TB-500

BPC-157

Category

Healing

Also known as

Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment

Body Protection Compound-157, Pentadecapeptide BPC 157

FDA approved

Clinical status

Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Phase 2 recruiting (NCT07437547); investigational.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Muscle recovery, wound healing, injury rehabilitation

Injury recovery, gut healing, joint and tendon repair

How it works

TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.

The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.

Typical dosing

2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) · 2x weekly for 4-6 weeks, then 1x weekly

250-500 mcg twice daily · 1-2x daily

Research dosing

2-2.5 mg twice weekly · 4-6 weeks loading, then maintenance · Subcutaneous or intramuscular injection

250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic

Typical duration

4-6 weeks loading, then maintenance

4-12 weeks in most research protocols

Administration

Subcutaneous or intramuscular injection

Subcutaneous injection near injury site, or systemic

Timing

Morning or evening

With or without food

Morning and evening (or near injury site timing)

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally well-tolerated in preclinical studies (Preclinical observation; long-term human safety data are limited.)
Injection site reactions
Headache

+7 more

Fatigue
Nausea
May trigger histamine release (Source advises caution for MCAS or histamine sensitivity.)
Theoretical risk of facilitating tumor cell migration (Source notes thymosin beta-4 is upregulated in metastatic cancers.)
Contraindicated with active cancer or cancer history (Source-supported contraindication note.)
Limited long-term safety data
WADA prohibited at all times (Listed in the source as prohibited on the 2025 WADA list.)

Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.)
Nausea (Listed by the source without frequency or causality information.)
Dizziness (Listed by the source without frequency or causality information.)

+6 more

Injection site reactions (Listed by the source without frequency or causality information.)
Fatigue (Listed by the source without frequency or causality information.)
Headache (Listed by the source without frequency or causality information.)
May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.)
Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.)
Limited long-term human safety data (The source itself notes limited long-term human safety information.)

Research summary

The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.

According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.

References

+2 more

+2 more

Full profile